Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

No longer available × INDUSTRY × denileukin diftitox × Clear all

Status

Completed 9 No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Recurrence 1 Neoplasms 1

Interventions

dabrafenib 4 trametinib 3 nilotinib 3 midostaurin 3 elotuzumab 3 Nivolumab 3 talimogene laherparepvec 2 regorafenib 2 Suspensions 2 Prednisone 2 Powders 2 Panobinostat 2 Melphalan 2 Lenalidomide 2 Ipilimumab 2 Everolimus 2 Dexamethasone 2 Bortezomib 2 zanubrutinib 1 zanidatamab 1 venetoclax 1 veliparib 1 tucatinib 1 tazemetostat 1 taletrectinib 1 surufatinib 1 sugemalimab 1 selitrectinib 1 ruxolitinib 1 rovalpituzumab tesirine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01432483 2015-01-26

Access Program With Denileukin Diftitox for the Treatment of Patients Currently Receiving Treatment With Commercially Available (Ontak)

Eisai Inc.

No longer available

Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡